• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Venrock Healthcare Capital Partners Iii, L.P. bought $1,241,685 worth of shares (99,129 units at $12.53) (SEC Form 4)

    1/24/24 8:24:01 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KALV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Venrock Healthcare Capital Partners III, L.P.

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    KalVista Pharmaceuticals, Inc. [ KALV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/22/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 01/22/2024 P 67,546 A $12.55(1) 4,527,197(2) I By Funds(3)
    Common Stock 01/23/2024 P 10,897 A $12.54(4) 4,538,094(5) I By Funds(3)
    Common Stock 01/24/2024 P 20,686 A $12.44(6) 4,558,780(7) I By Funds(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Venrock Healthcare Capital Partners III, L.P.

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Koh Bong Y

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    VHCP Co-Investment Holdings III, LLC

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    VHCP Management III, LLC

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    VHCP Management EG, LLC

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Venrock Healthcare Capital Partners EG, L.P.

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Shah Nimish P

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.37 to $12.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
    2. Consists of (i) 980,833 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 98,117 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,448,247 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
    3. VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
    4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.52 to $12.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
    5. Consists of (i) 983,698 shares held by VHCP3; (ii) 98,403 shares held by VHCP Co-3; and (iii) 3,455,993 shares held by VHCP EG.
    6. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.15 to $12.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
    7. Consists of (i) 989,136 shares held by VHCP3; (ii) 98,947 shares held by VHCP Co-3; and (iii) 3,470,697 shares held by VHCP EG.
    VHCP Co-Investment Holdings III, LLC, By: VHCP Management III, LLC, Its: Manager, By: /s/ Sherman G. Souther, Authorized Signatory 01/24/2024
    VHCP Management III, LLC, By: /s/ Sherman G. Souther, Authorized Signatory 01/24/2024
    Venrock Healthcare Capital Partners EG, L.P., By: VHCP Management EG, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory 01/24/2024
    Bong Koh, By: /s/ Sherman G. Souther, Attorney-in-fact 01/24/2024
    VHCP Management EG, LLC, By: /s/ Sherman G. Souther, Authorized Signatory 01/24/2024
    Nimish Shah, By: /s/ Sherman G. Souther, Attorney-in-fact 01/24/2024
    Venrock Healthcare Capital Partners III, L.P., By: VHCP Management III, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory 01/24/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KALV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KALV

    DatePrice TargetRatingAnalyst
    1/31/2025$19.00Mkt Outperform
    JMP Securities
    1/7/2025$30.00Buy
    TD Cowen
    12/18/2024$22.00Buy
    BofA Securities
    3/11/2022$48.00 → $42.00Buy
    Needham
    12/10/2021$50.00 → $48.00Buy
    Needham
    More analyst ratings

    $KALV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted three newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on May 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with t

      5/2/25 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Company will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 11:30 a.m. ET. A live webcast of the presentation will be available on the Company's website at www.kalvista.com. An audio archive will be available on KalVista's website for 30 days following the presentations. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a

      4/30/25 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

      -Up to $24 million in upfront and milestone payments, plus royalties- -Sebetralstat has potential to become first, oral on-demand treatment of HAE in Japan, underscoring commercial opportunity- -Kaken brings regional expertise and proven track record in commercializing innovative therapies- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd. (JPX: 4521.T) for sebetralstat, an investigational, oral on-demand treatment for hereditary angioedema (HAE). KalVista will receive an upfront payment of $11 million, with an additional payment o

      4/8/25 6:30:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALV
    Financials

    Live finance-specific insights

    See more
    • KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

      – Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call to discuss trial results today at 8:30 a.m. ET – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat as oral on-demand therapy for hereditary angioedema (HAE). KONFIDENT was the l

      2/13/24 6:30:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $235,500 worth of shares (25,000 units at $9.42) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      4/11/25 5:22:07 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 15,625 shares and sold $79,828 worth of shares (6,669 units at $11.97), increasing direct ownership by 3% to 287,811 units (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      3/10/25 6:43:21 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 5,000 shares and sold $23,988 worth of shares (2,394 units at $10.02), increasing direct ownership by 3% to 102,940 units (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/25/25 8:37:22 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

      SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      11/14/24 4:00:06 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

      SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      11/14/24 3:57:49 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by KalVista Pharmaceuticals Inc.

      SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      11/14/24 12:02:33 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALV
    SEC Filings

    See more
    • KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      4/8/25 7:30:22 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by KalVista Pharmaceuticals Inc.

      8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      3/17/25 4:01:13 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      3/12/25 4:41:06 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on KalVista Pharmaceuticals with a new price target

      JMP Securities initiated coverage of KalVista Pharmaceuticals with a rating of Mkt Outperform and set a new price target of $19.00

      1/31/25 7:03:28 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on KalVista Pharmaceuticals with a new price target

      TD Cowen initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $30.00

      1/7/25 7:55:33 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on KalVista Pharmaceuticals with a new price target

      BofA Securities initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $22.00

      12/18/24 7:36:39 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALV
    Leadership Updates

    Live Leadership Updates

    See more
    • KalVista Appoints Jeb Ledell as Chief Operating Officer

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. "I am pleased to welcome Jeb to KalVista at this key time in our evolution. His extensive experience in leading teams and driving efficiency within companies like ours makes him a valued addition to the team as we continue to evolve into a commercial entity," said Ben Palleiko, Chief Executive Officer of KalVista. "I am confident that his proven skills will help us to achieve our goal of delivering s

      12/16/24 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company's Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success. "I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors," said Ben Palleiko, Chief Executive Officer of KalVista. "His extensive biopharmaceutical and strategic experience will be a tremendous asset as the Company continues to progress sebetralstat towards global market approval and commercialization." "I am excited to join the KalVist

      11/26/24 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Appoints Brian Piekos as Chief Financial Officer

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Mr. Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the biotechnology sector. "Brian's deep industry experience and expertise in managing financial and capital strategies makes him a strong addition to KalVista as we prepare for the commercialization of sebetralstat," said Ben Palleiko, Chief Executive Officer at KalVista. "I'm excited to welcome Brian to KalVista, as he shares our commitment to patients and a results-driven approach to business excellence." "I am excited to join

      9/10/24 6:30:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $235,500 worth of shares (25,000 units at $9.42) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      4/11/25 5:22:07 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,498,661 worth of shares (161,700 units at $9.27) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/14/25 7:45:15 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $967,145 worth of shares (104,489 units at $9.26) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/11/25 7:51:08 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care